复方激素避孕药治疗子宫内膜异位症相关疼痛:证据的系统综述
本系统综述检索MEDLINE、Embase和Derwent Drug File数据库中的前瞻性临床研究,纳入9项随机对照试验和9项观察性研究,评估复方激素避孕药(雌激素-孕激素联合)对子宫内膜异位症相关疼痛的疗效。多数研究报告复方激素避孕药可显著减少痛经、盆腔痛和性交痛,连续给药似乎优于周期给药,但数据质量低。
要点
- 复方激素避孕药在多数研究中可显著减少子宫内膜异位症相关痛经、盆腔痛和性交痛。
- 连续给药似乎比周期给药更有用。
- 复方激素避孕药的止痛效果与口服孕激素和GnRH激动剂相似或更差。
核心结论
- 现有文献提示复方激素避孕药治疗可有效缓解子宫内膜异位症相关痛经、盆腔痛和性交痛,但支持数据质量低。
- 数据不足,无法得出任何特定复方激素避孕药治疗方案总体优越性的结论,也无法得出与其他方法相比的相对获益结论。
- 需要更多高质量研究来明确复方激素避孕药及其他治疗在子宫内膜异位症相关疼痛女性中的作用。
研究设计与样本
- 系统综述,检索MEDLINE、Embase和Derwent Drug File数据库中的前瞻性临床研究。
- 纳入9项随机对照试验和9项观察性研究。
- 研究对象为通过验证方法诊断的子宫内膜异位症女性。
- 干预措施为复方激素避孕药、活性对照药、安慰剂或无治疗。
主要发现
- 数据质量低:9项随机试验中仅2项为安慰剂对照,且多数试验未设盲。
- 多数研究报告复方激素避孕药从基线显著减少痛经、盆腔痛和性交痛。
- 连续给药似乎比周期给药更有用。
- 复方激素避孕药减少疼痛的效果与口服孕激素和GnRH激动剂相似或更差。
临床怎么用
- 原文未据此给出推荐。
局限性
- 数据质量低:仅2项随机试验为安慰剂对照,多数试验未设盲。
- 数据不足,无法得出任何特定复方激素避孕药治疗总体优越性的结论。
- 数据不足,无法得出复方激素避孕药与其他方法相比的相对获益结论。
- 需要更多高质量研究来明确复方激素避孕药及其他治疗的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To review the available clinical evidence on the use of combined hormonal contraceptive (CHC) agents (estrogen [E]-progestin combinations) for the treatment of endometriosis-related pain. DESIGN: A systematic review of the MEDLINE, Embase, and Derwent Drug File databases for prospective clinical studies. SETTING: Not applicable. PATIENT(S): Women with endometriosis diagnosed by validated means. INTERVENTION(S): Combined hormonal contraceptive agents, active comparators, placebo, or no treatment. MAIN OUTCOME MEASURE(S): Endometriosis-related pain (dysmenorrhea, pelvic pain, and dyspareunia). RESULT(S): Nine randomized controlled trials and nine observational studies met the inclusion criteria. The quality of data was low: only two of the nine randomized trials were placebo controlled, and most trials were not blinded. The CHC agents were reported to significantly reduce dysmenorrhea, pelvic pain, and dyspareunia from baseline in most studies; continuous administration seemed to be more useful than cyclic administration. The effectiveness of CHC agents for pain reduction was similar to or less than that of oral progestins and GnRH agonists. CONCLUSION(S): The available literature suggests that CHC treatment is effective for relief of endometriosis-related dysmenorrhea, pelvic pain, and dyspareunia; however, the supportive data are of low quality. Furthermore, insufficient data exist to reach conclusions about the overall superiority of any given CHC therapy, and the relative benefit in comparison to other approaches. Additional high-quality studies are needed to clarify the role of CHC agents and other treatments in women with endometriosis-related pain.
引用
- Jensen JT, Schlaff W, Gordon K, et al. Use of combined hormonal contraceptives for the treatment of endometriosis-related pain: a systematic review of the evidence. Fertil Steril. 2018. PMID: 29937152. doi:10.1016/j.fertnstert.2018.03.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。